Navigation Links
Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada
Date:3/3/2009

Clive V. Bennett is Named as the President and CEO of the New Canadian Entity

WHIPPANY, N.J., March 3 /PRNewswire/ -- Halo Pharmaceutical, a privately held specialty pharmaceutical company, has announced today that it is establishing a Canadian subsidiary to be called Halo Pharmaceutical Marketing (Canada) Ltd. This company will have its headquarters in Ontario, Canada, and its main purpose will be the marketing, sale and distribution of branded pharmaceutical products currently available in other major markets but not marketed in Canada. Halo is seeking, evaluating, and moving forward with opportunities for in-licensing and for the acquisition of branded products for both the US and Canadian markets from companies looking to rationalize their product portfolios. The Canadian subsidiary will be structured as a joint venture with CB&A Inc., a Canadian entity also based in Ontario, Canada. "We are excited about the opportunity to market a number of products in Canada as we continue to grow our North American business," commented Mohd Asif, Chief Financial Officer of Halo Pharmaceutical.

Halo has also named Clive V. Bennett as the President and CEO of this Canadian entity. Mr. Bennett, a Canadian pharmaceutical executive has over 38 years of experience in the global pharmaceutical industry. Prior to joining Halo Mr. Bennett worked for Patheon Inc for seven years. He held various top level positions at Patheon including the roles of Chief Scientific Officer, President of Patheon USA and President of Mova Pharmaceutical, a subsidiary of Patheon. Prior to his career at Patheon Mr. Bennett was Executive VP and Head of Global Operations for Hoechst Marion Roussel headquartered in Frankfurt, Germany.

"Some of the products we are intending to launch in the Canadian market can make a valuable contribution to the country's healthcare. I am looking forward to driving that effort on behalf of Halo," said Clive Bennett.

"We are glad to have someone of Clive's stature and ability working with us and helping us to grow our North American branded pharmaceutical business," said Al Rosenston, VP of Business Development for Halo.

About Halo Pharmaceutical:

Halo Pharmaceutical, headquartered in Whippany, NJ, is a specialty pharmaceutical company engaged in pharmaceutical branded product lifecycle management. Halo also offers full service state-of-the-art contract manufacturing, formulation development and laboratory testing services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Anti-Aging Medicine recently spoke at a popular international aesthetics conference for medical professionals ... on restoring his patients’ health and his growing practice. , Dr. George ...
(Date:8/22/2017)... ... 22, 2017 , ... Nurses at Apple Rehab Watch Hill , a ... training and certification in Closed Pulse Irrigation™ (CPI) for wound care. This ... the Centers for Medicare and Medicaid Services, to have a CPI machine that will ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty and ... and the struggles faced while hoping for a better life. “Without Love’s Beauty ... Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost 20 ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com recently ... to fight Fatigue . , As the stress of modern life continually makes ... the pace. Constant use of artificial stimulants can trap people in vicious high/low cycles ...
(Date:8/21/2017)... , ... August 22, 2017 , ... ... not without risk to health and safety. By learning and implementing best practices ... , In this webinar, attendees will gain a better understanding of a ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: